Mineralys Therapeutics, Inc. (MLYS) Misses Q3 EPS by 42c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. HNGE
10. SPY

Go back to Mineralys Therapeutics, Inc. (MLYS) Misses Q3 EPS by 42c

Mineralys Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

November 11, 2024 4:05 PM EST

Completed enrollment in pivotal Advance-HTN trial and anticipate topline data in March 2025

Completed enrollment ahead of schedule in pivotal Phase 3 Launch-HTN trial and anticipate delivering topline data in mid first half of 2025

Ongoing enrollment in Explore-CKD Phase 2 trial and anticipate delivering topline data in Q2 2025

Conference call today at 4:30 p.m. ET

RADNOR, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases... More